Vol 51, No 1 (2020)
Published online: 2020-03-01

open access

Page views 247
Article views/downloads 293
Get Citation

Connect on Social Media

Connect on Social Media

VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization

Matevz Skerget1, Barbara Skopec1, Matjaz Sever1
DOI: 10.2478/ahp-2020-0009
Acta Haematol Pol 2020;51(1):42-46.


Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% ( = 0.771) and the total number of collected stem cells were 7.0 × 10 and 6.7 × 10 per kg body weight ( = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only.

Article available in PDF format

View PDF Download PDF file